41 related articles for article (PubMed ID: 19661783)
1. The Warburg effect is genetically determined in inherited pheochromocytomas.
Favier J; Brière JJ; Burnichon N; Rivière J; Vescovo L; Benit P; Giscos-Douriez I; De Reyniès A; Bertherat J; Badoual C; Tissier F; Amar L; Libé R; Plouin PF; Jeunemaitre X; Rustin P; Gimenez-Roqueplo AP
PLoS One; 2009 Sep; 4(9):e7094. PubMed ID: 19763184
[TBL] [Abstract][Full Text] [Related]
2. Primary Functioning Hepatic Paraganglioma Treated by Laparoscopy: A Case Report.
Jiang C; Chen C; Zhou Y; Yang J; Yang J
J Clin Med; 2022 Dec; 11(24):. PubMed ID: 36555899
[TBL] [Abstract][Full Text] [Related]
3. Potential Biomarkers of Metastasizing Paragangliomas and Pheochromocytomas.
Snezhkina A; Pavlov V; Dmitriev A; Melnikova N; Kudryavtseva A
Life (Basel); 2021 Nov; 11(11):. PubMed ID: 34833055
[TBL] [Abstract][Full Text] [Related]
4. Transcriptome Analysis Reveals Significant Differences in Gene Expression of Malignant Pheochromocytoma or Paraganglioma.
Suh YJ; Park JH; Bilegsaikhan SE; Lee DJ
Int J Endocrinol; 2019; 2019():7014240. PubMed ID: 31205467
[TBL] [Abstract][Full Text] [Related]
5. CFC1 is a cancer stemness-regulating factor in neuroblastoma.
Chikaraishi K; Takenobu H; Sugino RP; Mukae K; Akter J; Haruta M; Kurosumi M; Endo TA; Koseki H; Shimojo N; Ohira M; Kamijo T
Oncotarget; 2017 Jul; 8(28):45046-45059. PubMed ID: 28620148
[TBL] [Abstract][Full Text] [Related]
6. Malignancy in Pheochromocytoma or Paraganglioma: Integrative Analysis of 176 Cases in TCGA.
Suh YJ; Choe JY; Park HJ
Endocr Pathol; 2017 Jun; 28(2):159-164. PubMed ID: 28386672
[TBL] [Abstract][Full Text] [Related]
7. Molecular and therapeutic advances in the diagnosis and management of malignant pheochromocytomas and paragangliomas.
Lowery AJ; Walsh S; McDermott EW; Prichard RS
Oncologist; 2013; 18(4):391-407. PubMed ID: 23576482
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of resection of extra-adrenal pheochromocytomas/paragangliomas in the laparoscopic era: a comparison with adrenal pheochromocytoma.
Goers TA; Abdo M; Moley JF; Matthews BD; Quasebarth M; Brunt LM
Surg Endosc; 2013 Feb; 27(2):428-33. PubMed ID: 22936431
[TBL] [Abstract][Full Text] [Related]
9. Diverse functional networks of Tbx3 in development and disease.
Washkowitz AJ; Gavrilov S; Begum S; Papaioannou VE
Wiley Interdiscip Rev Syst Biol Med; 2012; 4(3):273-83. PubMed ID: 22334480
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic tests and biomarkers for pheochromocytoma and extra-adrenal paraganglioma: from routine laboratory methods to disease stratification.
Eisenhofer G; Tischler AS; de Krijger RR
Endocr Pathol; 2012 Mar; 23(1):4-14. PubMed ID: 22180288
[TBL] [Abstract][Full Text] [Related]
11. Malignant pheochromocytomas and paragangliomas: a diagnostic challenge.
Gimm O; DeMicco C; Perren A; Giammarile F; Walz MK; Brunaud L
Langenbecks Arch Surg; 2012 Feb; 397(2):155-77. PubMed ID: 22124609
[TBL] [Abstract][Full Text] [Related]
12. Plasma methoxytyramine: a novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status.
Eisenhofer G; Lenders JW; Siegert G; Bornstein SR; Friberg P; Milosevic D; Mannelli M; Linehan WM; Adams K; Timmers HJ; Pacak K
Eur J Cancer; 2012 Jul; 48(11):1739-49. PubMed ID: 22036874
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA profiling of benign and malignant pheochromocytomas identifies novel diagnostic and therapeutic targets.
Meyer-Rochow GY; Jackson NE; Conaglen JV; Whittle DE; Kunnimalaiyaan M; Chen H; Westin G; Sandgren J; Stålberg P; Khanafshar E; Shibru D; Duh QY; Clark OH; Kebebew E; Gill AJ; Clifton-Bligh R; Robinson BG; Benn DE; Sidhu SB
Endocr Relat Cancer; 2010 Sep; 17(3):835-46. PubMed ID: 20621999
[TBL] [Abstract][Full Text] [Related]
14. Identification of potential gene markers and insights into the pathophysiology of pheochromocytoma malignancy.
Thouënnon E; Elkahloun AG; Guillemot J; Gimenez-Roqueplo AP; Bertherat J; Pierre A; Ghzili H; Grumolato L; Muresan M; Klein M; Lefebvre H; Ouafik L; Vaudry H; Plouin PF; Yon L; Anouar Y
J Clin Endocrinol Metab; 2007 Dec; 92(12):4865-72. PubMed ID: 17878247
[TBL] [Abstract][Full Text] [Related]
15. Expression of trophic amidated peptides and their receptors in benign and malignant pheochromocytomas: high expression of adrenomedullin RDC1 receptor and implication in tumoral cell survival.
Thouënnon E; Pierre A; Tanguy Y; Guillemot J; Manecka DL; Guérin M; Ouafik L; Muresan M; Klein M; Bertherat J; Lefebvre H; Plouin PF; Yon L; Anouar Y
Endocr Relat Cancer; 2010 Sep; 17(3):637-51. PubMed ID: 20483910
[TBL] [Abstract][Full Text] [Related]
16. Malignant pheochromocytomas and paragangliomas: molecular signaling pathways and emerging therapies.
Santarpia L; Habra MA; Jiménez C
Horm Metab Res; 2009 Sep; 41(9):680-6. PubMed ID: 19343618
[TBL] [Abstract][Full Text] [Related]
17. Development of differential diagnosis for benign and malignant pheochromocytomas.
Gao B; Kong F; Xu Z
Int J Urol; 2008 Sep; 15(9):771-7. PubMed ID: 18651863
[TBL] [Abstract][Full Text] [Related]
18. Candidate genes associated with malignant pheochromocytomas by genome-wide expression profiling.
Suh I; Shibru D; Eisenhofer G; Pacak K; Duh QY; Clark OH; Kebebew E
Ann Surg; 2009 Dec; 250(6):983-90. PubMed ID: 19661783
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
